Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive Remediation and Risperidone in First-Episode Schizophrenia
NCT00333177Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2006
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in schizophrenia (4 arms), sponsored by University of California, Los Angeles. Primary endpoints: MATRICS Consensus Cognitive Battery at 12 months, Global Functioning Scale: Role at 12 months and 1 more. Started Mar 2006; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00333177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333177.